Disease · HP_0012228
Tension-type headache
6 sourcesdiseases-2026-09-18-0.1.0
Cite this record
ConductScience Library. Tension-type headache. Diseases, record HP_0012228. Release diseases-2026-09-18-0.1.0, 18 Sept 2026. https://conductscience.org/library/diseases/HP_0012228
On this page
Disease
Names and IDs as Open Targets gives them. Its IDs in MeSH, Orphanet, the Disease Ontology and the NCI Thesaurus are those Open Targets states for it.
- Name
- Tension-type headache
- Open Targets ID
- HP_0012228
- Highest stage of its drugs
- Phase 3, for 2 of its 7 drugs, from ClinicalTrials.gov
Source Open Targets
Drugs7
The drugs Open Targets' clinical reports study for the disease, the highest stage first, then the most trial reports. The stage is Open Targets', the highest any of its sources reports for the pair, and each row names the sources that report it.
| Drug | ChEMBL ID | Type | Open Targets' stage | Stage reported by | Reports | Of them trials | Trials shown here | Source |
|---|---|---|---|---|---|---|---|---|
| ACETAMINOPHEN | CHEMBL112 | Small molecule | Phase 3 | ClinicalTrials.gov | 1 | 1 | 1 | Drugs and targets |
| BOTULINUM TOXIN TYPE A | CHEMBL4297862 | Protein | Phase 3 | ClinicalTrials.gov | 1 | 1 | 1 | Drugs and targets |
| DEXISOMETHEPTENE MUCATE | CHEMBL3707373 | Small molecule | Phase 2 | ClinicalTrials.gov | 1 | 1 | 1 | Drugs and targets |
| AMITRIPTYLINE | CHEMBL629 | Small molecule | Unknown | ClinicalTrials.gov | 1 | 1 | 1 | Drugs and targets |
| BUPIVACAINE | CHEMBL1098 | Small molecule | Unknown | ClinicalTrials.gov | 1 | 1 | 1 | Drugs and targets |
| DESVENLAFAXINE | CHEMBL1118 | Small molecule | Unknown | ClinicalTrials.gov | 1 | 1 | 1 | Drugs and targets |
| IBUPROFEN | CHEMBL521 | Small molecule | Unknown | ClinicalTrials.gov | 1 | 1 | 1 | Drugs and targets |
Targets8
The targets ChEMBL's mechanism records give for the disease's drugs, through Open Targets, the most drugs first. A mechanism record says what a drug acts on, not that the target causes the disease.
| Target | Protein | Its drugs that act on it | Mechanisms | Highest stage of those drugs | Gene in Genes | Source |
|---|---|---|---|---|---|---|
| PTGS1 | Cyclooxygenase | 2 | Cyclooxygenase inhibitor | Phase 3 | https://conductscience.org/library/genes/5742 | Drugs and targets |
| PTGS2 | Cyclooxygenase | 2 | Cyclooxygenase inhibitor | Phase 3 | https://conductscience.org/library/genes/5743 | Drugs and targets |
| SLC6A2 | Sodium-dependent noradrenaline transporter | 2 | Norepinephrine transporter inhibitor | Unknown | https://conductscience.org/library/genes/6530 | Drugs and targets |
| SLC6A4 | Sodium-dependent serotonin transporter | 2 | Serotonin transporter inhibitor | Unknown | https://conductscience.org/library/genes/6532 | Drugs and targets |
| FAAH | Fatty-acid amide hydrolase 1 | 1 | Anandamide amidohydrolase inhibitor | Phase 3 | https://conductscience.org/library/genes/2166 | Drugs and targets |
| SCN4A | Sodium channel protein type 4 subunit alpha | 1 | Sodium channel protein type IV alpha subunit blocker | Unknown | https://conductscience.org/library/genes/6329 | Drugs and targets |
| SNAP25 | Synaptosomal-associated protein 25 | 1 | Synaptosomal nerve-associated protein 25 (SNAP-25) hydrolytic enzyme | Phase 3 | https://conductscience.org/library/genes/6616 | Drugs and targets |
| TRPV1 | Transient receptor potential cation channel subfamily V member 1 | 1 | Vanilloid receptor opener | Phase 3 | https://conductscience.org/library/genes/7442 | Drugs and targets |
Trials7
Trials an Open Targets clinical report links to the disease, posted results first, then the largest. A trial is shown when the release's checks confirm its link to the disease and Drugs and targets shows its link to one of the disease's drugs.
| Trial | Title | Phase | Participants | Results first posted | Conditions | Drugs | Linked by | Source |
|---|---|---|---|---|---|---|---|---|
| NCT02423408 | Safety and Efficacy Study of TNX-201 Capsules for Treatment of Single Tension-Type Headache | Phase 2 | 165 | 2017-02-17 | Tension-Type Headache | DEXISOMETHEPTENE MUCATE | Its record names the disease | ClinicalTrials.gov |
| NCT07359248 | Desvenlafaxine for Preventive Treatment of Frequent Episodic Tension-type Headache | Not applicable | 432 | Tension Type Headache | DESVENLAFAXINE | Its record names the disease | ClinicalTrials.gov | |
| NCT07497646 | Repeated Bilateral Greater Occipital Nerve Blockade in Chronic Migraine and Chronic Tension-Type Headache | Not applicable | 290 | Chronic Migraine Headache, Chronic Tension-type Headache | BUPIVACAINE | Its record names the disease | ClinicalTrials.gov | |
| NCT06861738 | Effect of Parcetamol in Headach | Phase 3 | 100 | Headache | ACETAMINOPHEN | Its record names the disease | ClinicalTrials.gov | |
| NCT04857671 | Botulinum Toxin A in Frequent and Chronic Tension-type Headache | Phase 3 | 66 | Tension-Type Headache | BOTULINUM TOXIN TYPE A | Its record names the disease | ClinicalTrials.gov | |
| NCT05048914 | Migraine Abortive Treatment | 50 | Migraine Disorders | IBUPROFEN | Its record names the disease | ClinicalTrials.gov | ||
| NCT02746250 | Muscle Soreness and Stiffness in Patients With Chronic or Frequent Episodic Tension Type Headache. | Not applicable | 46 | Tension-type Headache | AMITRIPTYLINE | Its record names the disease | ClinicalTrials.gov |
Comparisons in its trials3
Comparisons Trial comparisons calculated in the trials shown here, most participants first. A comparison in one of these trials does not always compare a treatment for the disease, so read the two groups.
| Comparison | Group 1, with the outcome | Group 2, with the outcome | Participants | Trial | Source |
|---|---|---|---|---|---|
| TNX-201 vs Placebo: serious adverse events | 0 of 78 | 0 of 73 | 151 | NCT02423408 | Trial comparisons |
| TNX-201 vs Placebo: Number of Subjects Using Rescue Medication During the 24-hour Post-dose Period | 16 of 75 | 15 of 72 | 147 | NCT02423408 | Trial comparisons |
| TNX-201 vs Placebo: Number of Subjects With at Least a Two-category Improvement From Baseline at 2 Hours Post-dose in VAS Severity Category (Carvalho Responders) | 24 of 56 | 24 of 60 | 116 | NCT02423408 | Trial comparisons |
Papers from its trials0
The papers the trials shown here list on ClinicalTrials.gov as their results (RESULT) or as drawn from them (DERIVED), results first, newest first.
None in this release.
Data dates
The date of each source this release read.
Sources 6
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- NLM's MeSHNLM's terms
- Open TargetsCC0 1.0
- PubMedNLM's terms
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- NLM's MeSHNLM's
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this disease from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/diseases/v1/HP_0012228
GET https://conductscience.org/api/diseases/v1/HP_0012228/drugs